Cyclo(Gly-L-Pro)
Suppliers
Names
[ CAS No. ]:
3705-27-9
[ Name ]:
Cyclo(Gly-L-Pro)
[Synonym ]:
(8aS)-Hexahydropyrrolo[1,2-a]pyrazine-1,4-dione
3,6-dioxo-hexaphdro-pyrrolo-pyrazine
Cyclo-Gly-Pro
(S)-Hexahydropyrrolo[1,2-a]pyrazine-1,4-dione
cyclo(glycyl-l-prolyl)
hexahydropyrrolo[1,2-a]pyrazin-1,4-dione
GIO
cyclo-Gly-L-Pro
cyclo-(L-Pro-Gly)
Cyclo(-Gly-Pro)
(8AR)-HEXAHYDROPYRROLO[1,2-A]PYRAZINE-1,4-DIONE
CYCLO-(GLYCINE-L-PROLINE) INHIBITOR
Cyclo(pro-O-gly)
cyclo(Pro-Gly)
Pyrrolo(1,2-a)pyrazine-1,4-dione, hexahydro-, (S)-
Cyclo(prolylglycyl)
Pyrrolo[1,2-a]pyrazine-1,4-dione, hexahydro-, (8aS)-
Chemical & Physical Properties
[ Density]:
1.3±0.1 g/cm3
[ Boiling Point ]:
447.9±34.0 °C at 760 mmHg
[ Melting Point ]:
220-223℃
[ Molecular Formula ]:
C7H10N2O2
[ Molecular Weight ]:
154.167
[ Flash Point ]:
224.7±25.7 °C
[ Exact Mass ]:
154.074234
[ PSA ]:
49.41000
[ LogP ]:
-2.74
[ Vapour Pressure ]:
0.0±1.1 mmHg at 25°C
[ Index of Refraction ]:
1.569
[ Storage condition ]:
-15°C
[ Water Solubility ]:
DMSO: >10mg/mL
MSDS
Safety Information
[ Hazard Codes ]:
Xi
[ RIDADR ]:
NONH for all modes of transport
[ HS Code ]:
2933990090
Customs
[ HS Code ]: 2933990090
[ Summary ]:
2933990090. heterocyclic compounds with nitrogen hetero-atom(s) only. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%
Articles
Scand. J. Immunol. 76(2) , 131-40, (2012)
This study was undertaken to isolate active secondary metabolites from immunostimulatory Alcaligenes faecalis FY-3 and evaluate their activities using grass carp Ctenopharyngodon idella kidney (CIK) c...
Proc. Natl. Acad. Sci. U. S. A. 86 , 7880, (1989)
Calcium plays a crucial role in many cellular processes. Its functions are directly dependent on the high specificity for Ca2+ exhibited by the proteins and ion carriers that bind divalent ions. To el...
Neuropharmacology 53(6) , 749-62, (2007)
The current study describes the neuroprotective effects of an endogenous diketopiperazine, cyclo-glycyl-proline (cyclic GP), in rats with hypoxic-ischemic brain injury and the pre-clinical development...